Ideeea Therapeutics has closed a €2.3 million seed funding round to drive the development of advanced therapy medicinal products, following an open science approach and aiming for high clinical impact.
This financing round will make it possible to accelerate AGAcell, a product developed by Ideeea. AGAcell is a preclinical research program that explores the intradermal administration of a patented stem cell formulation, combined with a bioactive molecule, for the therapeutic treatment of androgenetic alopecia.
According to the company—led by José Ángel Sánchez and Marisa Berenguer—“androgenetic alopecia goes beyond the aesthetic dimension, as progressive hair loss removes the natural protective barrier and chronically exposes the scalp to ultraviolet radiation, which is associated with increased photoaging and a higher risk of certain skin carcinomas.”
Several studies also point to its negative impact on self-esteem and mental health. To address this challenge, AGAcell is based on a potential therapy that explores the ability to restore the cellular microenvironment of the hair follicle, thereby promoting hair regeneration through a minimally invasive, non-surgical procedure. In addition, the program is led scientifically by Dr. Eduardo López Bran, a dermatologist specializing in trichology—the branch of dermatology dedicated to the study of hair and the scalp—and Head of the Dermatology Department at Hospital Clínico San Carlos (Madrid).
Open Innovation
Ideeea Therapeutics follows an open innovation model, supported by multiple partnerships with public and private hospitals and research centers, enabling the company to advance its advanced therapies (ATMPs) from research through to product manufacturing in compliance with Good Manufacturing Practice (GMP) guidelines.
“At Ideeea Therapeutics, we are committed to regenerative medicine grounded in scientific evidence and accessible to society. With the AGAcell program, we are embarking on a path that we believe will allow us to deliver meaningful therapeutic alternatives to real clinical needs, always under the rigor of research and health regulation,” says Marisa Berenguer, CEO of Ideeea Therapeutics.
